Grove Biopharma Launches with a Novel Biotherapeutic Modality Platform; Portal Innovations Leads Oversubscribed Seed-Stage Investment Share Article Leverages Biomaterial Discoveries and Insights from Award Winning Scientist Nathan Gianneschi, Ph.D. With an Initial Focus on Neurodegenerative Diseases Professor Gianneschi’s protein-like polymer (PLP) platform is a revolutionary innovation at the interface between materials engineering, biology, chemistry, and data science with the potential to address important biological disease targets including those classically considered to be undruggable. CHICAGO (PRWEB) May 10, 2021 Portal Innovations, a premier life sciences venture development engine, today announced that Grove Biopharma has successfully closed an oversubscribed $4 million seed round and will become a portfolio member at its Fulton Labs location. Other noteworthy participants in the financing include Joe Mansueto, Skydeck Capital, and Walder Ventures. Grove is a platform biotech company, spinning out of Northwestern University, pioneering the discovery and development of an innovative proteomimetic therapeutic modality. Proceeds from this round will advance the lead program targeting an intracellular protein-protein interaction relevant to neurodegenerative and inflammatory diseases. Portal Innovations founder and CEO, John Flavin, will join Grove Biopharma’s board of directors.